Verano Holdings (VRNO) Common Equity (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Common Equity of $688.3 million for Q1 2026, down 26.9% year-over-year from $941.6 million in Q1 2025, and down 2.25% quarter-over-quarter from $704.2 million in Q4 2025.
Verano Holdings (VRNO) Common Equity (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Common Equity for 6 consecutive years, with $688.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 26.9% year-over-year to $688.3 million; the TTM figure through Mar 2026 stood at $688.3 million (down 26.9% YoY), while the FY2025 annual figure was $704.2 million, down 25.94% from the prior year.
- Common Equity slipped to $688.3 million in Q1 2026 per VRNO's latest filing, from $704.2 million in the prior quarter.
- Across five years, Common Equity topped out at $1.5 billion in Q2 2022 and bottomed at $688.3 million in Q1 2026.
- Historically, Common Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Common Equity surged 6973.1% — and 2025, when it decreased 27.27%.
- Verano Holdings' Common Equity stood at $1.3 billion in 2022, then declined by 7.56% to $1.2 billion in 2023, then fell by 23.33% to $950.8 million in 2024, then declined by 25.94% to $704.2 million in 2025, then declined by 2.25% to $688.3 million in 2026.
- Business Quant data shows VRNO's Common Equity at $688.3 million in Q1 2026, $704.2 million in Q4 2025, and $885.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Verano Holdings | 438.82 Mn | 353.62 Mn | 99.70 Mn | 676.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 676.53 Mn |
| Mar 31, 2026 | 688.35 Mn |
| Dec 31, 2025 | 704.16 Mn |
| Sep 30, 2025 | 885.86 Mn |
| Jun 30, 2025 | 927.23 Mn |
| Mar 31, 2025 | 941.60 Mn |
| Dec 31, 2024 | 950.82 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.22 Bn |
| Mar 31, 2024 | 1.24 Bn |
| Dec 31, 2023 | 1.24 Bn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | 1.33 Bn |
| Mar 31, 2023 | 1.34 Bn |
| Dec 31, 2022 | 1.34 Bn |
| Sep 30, 2022 | 1.54 Bn |
| Jun 30, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.48 Bn |
| Sep 30, 2021 | 42.40 Mn |
| Jun 30, 2021 | 21.90 Mn |